Are CPT codes 87624, 88175, 86632, 87590, and 87661 correct for a routine gynecological examination, including Pap smear with Human Papillomavirus (HPV) testing, and screenings for Gonorrhea, Trichomonas, and Chlamydia, in an asymptomatic adult female of reproductive age?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

CPT Code Review for Routine Gynecological Screening

Most of your CPT codes are correct, but CPT 86632 (Chlamydia IgM antibody) is incorrect and should be replaced with a nucleic acid amplification test (NAAT) code for Chlamydia, such as CPT 87491 or 87492.

Correct CPT Codes

Pap Smear and HPV Testing

  • CPT 88175 (liquid-based cytology, thin-layer preparation) is the appropriate code for the Pap smear component 1
  • CPT 87624 (HPV DNA detection, high-risk types) is correct for high-risk HPV testing, which is recommended for women aged 30-65 years as part of co-testing with Pap smears every 5 years 2, 3

STI Screening Codes

  • CPT 87590 (Neisseria gonorrhoeae detection by nucleic acid, direct probe) is appropriate for gonorrhea screening 2
  • CPT 87661 (Trichomonas vaginalis amplified probe technique) is correct for trichomoniasis screening 2

The Critical Error: Chlamydia Testing

CPT 86632 (Chlamydia IgM antibody) is NOT appropriate for routine screening. This code represents serologic antibody testing, which is not recommended for Chlamydia screening 2.

Correct Chlamydia Codes

You should use nucleic acid amplification testing (NAAT) instead, which is the gold standard for Chlamydia screening:

  • CPT 87491 (Chlamydia trachomatis, amplified probe technique) or
  • CPT 87492 (Chlamydia trachomatis, quantification)

The USPSTF recommends screening sexually active women aged 24 years and younger, and older women at increased risk, using nucleic acid amplification tests 2. Research confirms that NAAT methods from cervical specimens have sensitivities of 93-99% and specificities of 95.5-99% 4.

Clinical Context and Appropriateness

Age-Appropriate Screening

The appropriateness of these tests depends on the patient's age:

  • Ages 21-29: Pap test alone every 3 years is recommended; HPV testing is NOT recommended for routine screening in this age group 3
  • Ages 30-65: Co-testing with Pap + HPV every 5 years is preferred, or Pap alone every 3 years 2, 3

STI Screening Indications

  • Gonorrhea and Chlamydia screening is recommended for sexually active women aged 24 years and younger, and for older women at increased risk 2
  • Trichomonas screening is not universally recommended for asymptomatic women, but can be performed during routine examination 2

Common Pitfalls to Avoid

Do not use HPV testing as a standalone screening test in women under 30 years 3. The CDC specifically recommends against HPV testing for women aged 21-29 years for routine screening 3.

Avoid serologic testing for Chlamydia when nucleic acid amplification tests are available and clinically indicated 2. Antibody tests like CPT 86632 are not appropriate for screening purposes.

Ensure the patient meets age and risk criteria for each screening test ordered. The USPSTF provides clear B-grade recommendations for Chlamydia and gonorrhea screening in specific populations 2.

Summary of Recommended Changes

Keep these codes:

  • CPT 88175 (Pap smear)
  • CPT 87624 (HPV high-risk types) - if patient is ≥30 years
  • CPT 87590 (Gonorrhea NAAT)
  • CPT 87661 (Trichomonas NAAT)

Replace this code:

  • CPT 86632 (Chlamydia IgM)CPT 87491 or 87492 (Chlamydia NAAT)

References

Guideline

CPT Codes and Screening Guidelines for Cervical Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

HPV Testing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the management approach for patients with abnormal Pap (Papanicolaou) smear results, specifically ASCUS (Atypical Squamous Cells of Undetermined Significance)?
What are the next steps for a 33-year-old female with a Papanicolaou (Pap) smear result showing Atypical Squamous Cells of Undetermined Significance (ASCUS) and positive for high-risk Human Papillomavirus (HPV) types, specifically E6/E7, with no prior history of abnormal Pap results?
What are the next steps for a 55-year-old female with a Papanicolaou (Pap) smear result showing Atypical Squamous Cells of Undetermined Significance (ASCUS) and a positive Human Papillomavirus (HPV) test with an unknown strain?
What is the significance of a new Human Papillomavirus (HPV) detection on a Papanicolaou (Pap) test in a patient with previously negative results, and could it indicate infidelity in a monogamous relationship?
What are the next steps for a non-sexually active female with an abnormal Pap (Papanicolau) test result?
How to evaluate organ damage in an elderly patient with acute hypertension in a long-term care setting?
What is the best antibiotic treatment for an elderly female patient with bilateral otitis media and a known allergy to cephalexin (a type of beta-lactam antibiotic)?
What is the equivalent dose of Librium (chlordiazepoxide) to 4mg of lorazepam (Ativan) in a patient?
What are the primary risk factors for developing tuberculosis (TB), especially in patients with compromised immune systems, such as those with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) or diabetes?
What components should be included in a History of Present Illness (HPI) for a patient with severe protein calorie malnutrition?
What is the best management approach for a patient with double site fractures at ribs 4, 5, and 6 following a road traffic accident (RTA)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.